ISV 208Alternative Names: ISV-208
Latest Information Update: 26 Apr 2007
At a glance
- Originator InSite Vision
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 26 Apr 2007 Discontinued - Phase-I/II for Ocular hypertension in USA (Ophthalmic)
- 26 Apr 2007 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic)